498 related articles for article (PubMed ID: 25421657)
1. Beyond the island: epigenetic biomarkers of colorectal and prostate cancer.
Savio AJ; Bapat B
Methods Mol Biol; 2015; 1238():103-24. PubMed ID: 25421657
[TBL] [Abstract][Full Text] [Related]
2. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
3. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer.
Belshaw NJ; Elliott GO; Williams EA; Bradburn DM; Mills SJ; Mathers JC; Johnson IT
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1495-501. PubMed ID: 15342451
[TBL] [Abstract][Full Text] [Related]
4. Targeting aberrant chromatin structure in colorectal carcinomas.
Konishi K; Issa JP
Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
[TBL] [Abstract][Full Text] [Related]
5. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.
Yegnasubramanian S; Haffner MC; Zhang Y; Gurel B; Cornish TC; Wu Z; Irizarry RA; Morgan J; Hicks J; DeWeese TL; Isaacs WB; Bova GS; De Marzo AM; Nelson WG
Cancer Res; 2008 Nov; 68(21):8954-67. PubMed ID: 18974140
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
7. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
Nakayama M; Gonzalgo ML; Yegnasubramanian S; Lin X; De Marzo AM; Nelson WG
J Cell Biochem; 2004 Feb; 91(3):540-52. PubMed ID: 14755684
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic applications of epigenetics.
Miyamoto K; Ushijima T
Jpn J Clin Oncol; 2005 Jun; 35(6):293-301. PubMed ID: 15930038
[TBL] [Abstract][Full Text] [Related]
9. Promoter CpG island methylation markers in colorectal cancer: the road ahead.
Draht MX; Riedl RR; Niessen H; Carvalho B; Meijer GA; Herman JG; van Engeland M; Melotte V; Smits KM
Epigenomics; 2012 Apr; 4(2):179-94. PubMed ID: 22449189
[TBL] [Abstract][Full Text] [Related]
10. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
11. [Detection of DNA hypermethylation as a potential biomarker for prostate cancer].
Tilandyová P; Kajo K; Kliment J; Plank L; Lasabová Z
Klin Onkol; 2010; 23(5):293-9. PubMed ID: 21061679
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
Stirzaker C; Song JZ; Davidson B; Clark SJ
Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis of genetic and epigenetic alterations in cancer.
Toyota M; Suzuki H; Yamamoto E; Yamano H; Imai K; Shinomura Y
Epigenomics; 2009 Dec; 1(2):291-9. PubMed ID: 22122704
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma.
Ribarska T; Ingenwerth M; Goering W; Engers R; Schulz WA
Cancer Genomics Proteomics; 2010; 7(2):51-60. PubMed ID: 20335518
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation markers in colorectal cancer.
Kim MS; Lee J; Sidransky D
Cancer Metastasis Rev; 2010 Mar; 29(1):181-206. PubMed ID: 20135198
[TBL] [Abstract][Full Text] [Related]
18. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation and cancer.
Kulis M; Esteller M
Adv Genet; 2010; 70():27-56. PubMed ID: 20920744
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation.
Bastian PJ; Yegnasubramanian S; Palapattu GS; Rogers CG; Lin X; De Marzo AM; Nelson WG
Eur Urol; 2004 Dec; 46(6):698-708. PubMed ID: 15548435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
